Lyell Immunopharma, Inc. (LYEL)
23.07
+0.06
(+0.26%)
USD |
NASDAQ |
Feb 27, 10:44
Lyell Immunopharma Research and Development Expense (Quarterly) : 25.61M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Insmed, Inc. | 254.91M |
| Nektar Therapeutics | 27.25M |
| GT Biopharma, Inc. | 0.634M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Vertex Pharmaceuticals, Inc. | 973.70M |